People considering high frequency 10 kHz spinal cord stimulation want two things: relief that lasts and a clear price they can plan around. HF10 therapy, delivered by the Nevro Senza system, is an FDA ...
On April 3, 2025, Nevro Corp. filed a notice of data breach with the Attorney General of Texas after discovering that information in the company’s possession was subject to unauthorized access. In ...
REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic ...
REDWOOD CITY, Calif., Jan. 21, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic ...
Reaffirms Full-Year 2024 Revenue Guidance and Raises Full-Year 2024 Adjusted EBITDA Guidance REDWOOD CITY, Calif., Nov. 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device ...
Analysis Marks the First Study of Spinal Cord Stimulation to Demonstrate Long-term, Significant, and Clinically Meaningful Reductions in HbA1c and Weight in Study Participants with Painful Diabetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback